pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
PD-1 · news · pharmadog
← back to PD-1
News · PD-1
63
stories
3d
5 biggest venture capital raises of Q3 2026
biospace
4d
The top biopharma conferences in 2027
biopharma dive
8d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
10d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
11d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
11d
Summit snags $2B investment from AstraZeneca, clearing financial overhang
biospace
11d
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push
biopharma dive
11d
Highlight Therapeutics illuminates positive ph. 2 topline data in high-risk skin cancer
fiercebiotech
11d
AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
fiercebiotech
12d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
18d
Compass vows to press on with FDA application despite new trial request
biospace
22d
China plans to transform biotech sector into $522B powerhouse by 2030
biospace
25d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
26d
Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results
biopharma dive
26d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
26d
Unlocking cell surface protein research with site-specific labeling
biospace
26d
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
Sep 9, 26
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
Sep 9, 26
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
fiercebiotech
Sep 3, 26
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
biospace
Sep 3, 26
Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharma dive
Sep 3, 26
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
biospace
Aug 26, 26
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
Aug 26, 26
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
Aug 19, 26
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
Aug 17, 26
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
Aug 17, 26
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
Aug 17, 26
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
Aug 10, 26
BMS picks Texas for new $2.3B manufacturing campus
biospace
Aug 10, 26
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
← prev
page 1 of 3
next →
